Literature DB >> 23335053

The cellular prion protein traps Alzheimer's Aβ in an oligomeric form and disassembles amyloid fibers.

Nadine D Younan1, Claire J Sarell, Paul Davies, David R Brown, John H Viles.   

Abstract

There is now strong evidence to show that the presence of the cellular prion protein (PrP(C)) mediates amyloid-β (Aβ) neurotoxicity in Alzheimer's disease (AD). Here, we probe the molecular details of the interaction between PrP(C) and Aβ and discover that substoichiometric amounts of PrP(C), as little as 1/20, relative to Aβ will strongly inhibit amyloid fibril formation. This effect is specific to the unstructured N-terminal domain of PrP(C). Electron microscopy indicates PrP(C) is able to trap Aβ in an oligomeric form. Unlike fibers, this oligomeric Aβ contains antiparallel β sheet and binds to a oligomer specific conformational antibody. Our NMR studies show that a specific region of PrP(C), notably residues 95-113, binds to Aβ oligomers, but only once Aβ misfolds. The ability of PrP(C) to trap and concentrate Aβ in an oligomeric form and disassemble mature fibers suggests a mechanism by which PrP(C) might confer Aβ toxicity in AD, as oligomers are thought to be the toxic form of Aβ. Identification of a specific recognition site on PrP(C) that traps Aβ in an oligomeric form is potentially a therapeutic target for the treatment of Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23335053      PMCID: PMC3767752          DOI: 10.1096/fj.12-222588

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  52 in total

1.  Local structural plasticity of the prion protein. Analysis of NMR relaxation dynamics.

Authors:  J H Viles; D Donne; G Kroon; S B Prusiner; F E Cohen; H J Dyson; P E Wright
Journal:  Biochemistry       Date:  2001-03-06       Impact factor: 3.162

2.  Prion protein expression in senile plaques in Alzheimer's disease.

Authors:  I Ferrer; R Blanco; M Carmona; B Puig; R Ribera; M J Rey; T Ribalta
Journal:  Acta Neuropathol       Date:  2001-01       Impact factor: 17.088

Review 3.  Three-dimensional structures of prion proteins.

Authors:  K Wüthrich; R Riek
Journal:  Adv Protein Chem       Date:  2001

4.  Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo.

Authors:  Dominic M Walsh; Igor Klyubin; Julia V Fadeeva; William K Cullen; Roger Anwyl; Michael S Wolfe; Michael J Rowan; Dennis J Selkoe
Journal:  Nature       Date:  2002-04-04       Impact factor: 49.962

5.  Identification of hot regions of the Abeta-IAPP interaction interface as high-affinity binding sites in both cross- and self-association.

Authors:  Erika Andreetto; Li-Mei Yan; Marianna Tatarek-Nossol; Aleksandra Velkova; Ronald Frank; Aphrodite Kapurniotu
Journal:  Angew Chem Int Ed Engl       Date:  2010-04-12       Impact factor: 15.336

6.  Interaction between human prion protein and amyloid-beta (Abeta) oligomers: role OF N-terminal residues.

Authors:  Shugui Chen; Satya P Yadav; Witold K Surewicz
Journal:  J Biol Chem       Date:  2010-06-24       Impact factor: 5.157

7.  Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure.

Authors:  V N Uversky; J Li; A L Fink
Journal:  J Biol Chem       Date:  2001-09-11       Impact factor: 5.157

8.  Neurodegenerative disease: amyloid pores from pathogenic mutations.

Authors:  Hilal A Lashuel; Dean Hartley; Benjamin M Petre; Thomas Walz; Peter T Lansbury
Journal:  Nature       Date:  2002-07-18       Impact factor: 49.962

9.  Substoichiometric levels of Cu2+ ions accelerate the kinetics of fiber formation and promote cell toxicity of amyloid-{beta} from Alzheimer disease.

Authors:  Claire J Sarell; Shane R Wilkinson; John H Viles
Journal:  J Biol Chem       Date:  2010-10-25       Impact factor: 5.157

10.  Prion protein and Abeta-related synaptic toxicity impairment.

Authors:  Anna Maria Calella; Mélissa Farinelli; Mario Nuvolone; Osvaldo Mirante; Rita Moos; Jeppe Falsig; Isabelle M Mansuy; Adriano Aguzzi
Journal:  EMBO Mol Med       Date:  2010-08       Impact factor: 12.137

View more
  39 in total

1.  MEK1 transduces the prion protein N2 fragment antioxidant effects.

Authors:  C L Haigh; A R McGlade; S J Collins
Journal:  Cell Mol Life Sci       Date:  2014-11-13       Impact factor: 9.261

2.  Shedding light on prion disease.

Authors:  Markus Glatzel; Luise Linsenmeier; Frank Dohler; Susanne Krasemann; Berta Puig; Hermann C Altmeppen
Journal:  Prion       Date:  2015       Impact factor: 3.931

Review 3.  Amyloid β Protein and Alzheimer's Disease: When Computer Simulations Complement Experimental Studies.

Authors:  Jessica Nasica-Labouze; Phuong H Nguyen; Fabio Sterpone; Olivia Berthoumieu; Nicolae-Viorel Buchete; Sébastien Coté; Alfonso De Simone; Andrew J Doig; Peter Faller; Angel Garcia; Alessandro Laio; Mai Suan Li; Simone Melchionna; Normand Mousseau; Yuguang Mu; Anant Paravastu; Samuela Pasquali; David J Rosenman; Birgit Strodel; Bogdan Tarus; John H Viles; Tong Zhang; Chunyu Wang; Philippe Derreumaux
Journal:  Chem Rev       Date:  2015-03-19       Impact factor: 60.622

4.  PrP-grafted antibodies bind certain amyloid β-protein aggregates, but do not prevent toxicity.

Authors:  David Mengel; Wei Hong; Grant T Corbett; Wen Liu; Alexandra DeSousa; Laura Solforosi; Cheng Fang; Matthew P Frosch; John Collinge; David A Harris; Dominic M Walsh
Journal:  Brain Res       Date:  2018-12-26       Impact factor: 3.252

5.  Interaction between prion protein and Aβ amyloid fibrils revisited.

Authors:  Krzysztof Nieznanski; Krystyna Surewicz; Shugui Chen; Hanna Nieznanska; Witold K Surewicz
Journal:  ACS Chem Neurosci       Date:  2014-04-01       Impact factor: 4.418

6.  A d-enantiomeric peptide interferes with heteroassociation of amyloid-β oligomers and prion protein.

Authors:  Nadine S Rösener; Lothar Gremer; Elke Reinartz; Anna König; Oleksandr Brener; Henrike Heise; Wolfgang Hoyer; Philipp Neudecker; Dieter Willbold
Journal:  J Biol Chem       Date:  2018-08-21       Impact factor: 5.157

Review 7.  Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases.

Authors:  Maxime Béland; Xavier Roucou
Journal:  Prion       Date:  2014 Jan-Feb       Impact factor: 3.931

Review 8.  Binding between Prion Protein and Aβ Oligomers Contributes to the Pathogenesis of Alzheimer's Disease.

Authors:  Chang Kong; Hao Xie; Zhenxing Gao; Ming Shao; Huan Li; Run Shi; Lili Cai; Shanshan Gao; Taolei Sun; Chaoyang Li
Journal:  Virol Sin       Date:  2019-05-15       Impact factor: 4.327

9.  Cellular Prion Protein Mediates the Disruption of Hippocampal Synaptic Plasticity by Soluble Tau In Vivo.

Authors:  Tomas Ondrejcak; Igor Klyubin; Grant T Corbett; Graham Fraser; Wei Hong; Alexandra J Mably; Matthew Gardener; Jayne Hammersley; Michael S Perkinton; Andrew Billinton; Dominic M Walsh; Michael J Rowan
Journal:  J Neurosci       Date:  2018-10-24       Impact factor: 6.167

10.  Soluble prion protein and its N-terminal fragment prevent impairment of synaptic plasticity by Aβ oligomers: Implications for novel therapeutic strategy in Alzheimer's disease.

Authors:  Jonah J Scott-McKean; Krystyna Surewicz; Jin-Kyu Choi; Vernon A Ruffin; Ahlam I Salameh; Krzysztof Nieznanski; Alberto C S Costa; Witold K Surewicz
Journal:  Neurobiol Dis       Date:  2016-03-03       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.